Geneva, Oct. 21 -- International Clinical Trials Registry received information related to the study (NCT07204236) titled 'Study to Evaluate Immunogenicity and Safety of TVAX-008 Injection in Non/Treated Chronic Hepatitis B Patients With HBsAg=20IU/ml or HBsAg Negative Without Serological Conversion' on Sept. 24.

Study Type: Interventional

Study Design: Allocation: N/A. Intervention model: Single Group Assignment. Primary purpose: Treatment. Masking: None (Open Label).

Primary Sponsor: Grand Theravac Life Sciences (Nanjing) Co., Ltd.

Condition: Chronic Hepatitis B

Intervention: Drug: TVAX-008

Recruitment Status: Not recruiting

Phase: Early Phase 1

Date of First Enrollment: January 18, 2024

Target Sample Size: 20

Countries ...